These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12585231)

  • 1. Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps.
    Danhof M; Visser SA
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():127-8. PubMed ID: 12585231
    [No Abstract]   [Full Text] [Related]  

  • 2. Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario.
    Barbanoj MJ; Valle M; Kulisevsky J; Pérez V; Gambús P
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():139-44. PubMed ID: 12575481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaco-electroencephalography and pharmacokinetic/pharmacodynamic modeling in basic research: focus on human pharmacology.
    Valle M; Barbanoj MJ; Jané F
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():129-37. PubMed ID: 12575480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaco-electroencephalography in Phase I.
    Luthringer R; Boeijinga PH
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():95. PubMed ID: 12809085
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimalarial drug discovery: efficacy models for compound screening.
    Fidock DA; Rosenthal PJ; Croft SL; Brun R; Nwaka S
    Nat Rev Drug Discov; 2004 Jun; 3(6):509-20. PubMed ID: 15173840
    [No Abstract]   [Full Text] [Related]  

  • 6. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic relationships: basic concepts.
    Trocóniz IF
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():125-6. PubMed ID: 12575479
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of basic principles of fractals and their application to pharmacokinetics.
    Marsh RE; Riauka TA; McQuarrie SA
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):278-88. PubMed ID: 18551095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaco-EEG: from cellular to the network level. EEG beta spectral power as a biomarker for GABAergic inhibition and its role in the assessment of AEDs.
    Lopes da Silva F
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():3. PubMed ID: 12575462
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of systems approaches on biological problems in drug discovery.
    Hood L; Perlmutter RM
    Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
    [No Abstract]   [Full Text] [Related]  

  • 11. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabonomics in pharmaceutical R&D.
    Lindon JC; Holmes E; Nicholson JK
    FEBS J; 2007 Mar; 274(5):1140-51. PubMed ID: 17298438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in pharmacokinetic modeling.
    Ahmad AM
    Biopharm Drug Dispos; 2007 Apr; 28(3):135-43. PubMed ID: 17295411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modeling in anesthesia, intensive care and pain medicine.
    Sadean MR; Glass PS
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):463-8. PubMed ID: 19412091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
    Korstanje C
    Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643
    [No Abstract]   [Full Text] [Related]  

  • 17. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
    Vrijens B; Goetghebeur E
    Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative proteomics for drug toxicity.
    Gao Y; Holland RD; Yu LR
    Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting QSAR models in lead optimization.
    Gedeck P; Lewis RA
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):569-75. PubMed ID: 18600573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
    Ertl HC
    Curr Opin Mol Ther; 2002 Dec; 4(6):601-5. PubMed ID: 12596363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.